EHA HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSION: REVUMENIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY KMT2AR ACUTE LEUKEMIA
OR
Chair
Dr. Jorge Cortes
Panelists
Dr. Julie Bergeron
Dr. Aniket Bankar
This program has been made possible through unrestricted support from Astellas.
Studies/trials discussed:
- Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study
